Treating asthma in the time of COVID
Journal of Allergy and Clinical Immunology · 2023-04 · 151 (4) · 809-817
DOI: 10.1016/j.jaci.2022.12.800 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-04. Verfasst von Tara F Carr und 8 weiteren Autor:innen. Beteiligte Einrichtung: Asthma and Airway Disease Research Center, University of Arizona, Tucson. Hauptthemen laut MEDLINE: COVID-19, Asthma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
The Precision Interventions for Severe and/or Exacerbation-Prone Asthma clinical trials network is actively assessing novel treatments for severe asthma during the coronavirus disease (COVID-19) pandemic and has needed to adapt to various clinical dilemmas posed by the COVID-19 pandemic. Pharmacologic interactions between established asthma therapies and novel drug interventions for COVID-19 infection, including antivirals, biologics, and vaccines, have emerged as a critical and unanticipated issue in the clinical care of asthma. In particular, impaired metabolism of some long-acting beta-2 agonists by the cytochrome P4503A4 enzyme in the setting of antiviral treatment using ritonavir-boosted nirmatrelvir (NVM/r, brand name Paxlovid) may increase risk for adverse cardiovascular events. Although available data have documented the potential for such interactions, these issues are largely unappreciated by clinicians who treat asthma, or those dispensing COVID-19 interventions in patients who happen to have asthma. Because these drug-drug interactions have not previously been relevant to patient care, clinicians have had no guidance on management strategies to reduce potentially serious interactions between treatments for asthma and COVID-19. The Precision Interventions for Severe and/or Exacerbation-Prone Asthma network considered the available literature and product information, and herein share our considerations and plans for treating asthma within the context of these novel COVID-19-related therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Asthma and Airway Disease Research Center, University of Arizona, Tucson.
- Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh.
- Samuel Bronfman Department of Medicine, Icahn School of Medicine at Mount Sinai, New York.
- Division of Allergy and Immunology, Department of Pediatrics, Boston Children's Hospital, Boston.
- The University of Colorado School of Medicine and Children's Hospital Colorado, Department of Pediatrics, The Breathing Institute, Aurora.
- Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of California, Davis School of Medicine, UC Davis Lung Center, Sacramento.
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- NIEHS NIH HHS
- NIAID NIH HHS
- NHLBI
Zitieren
APA
Carr, T. F., Fajt, M. L., Kraft, M., Phipatanakul, W., Szefler, S. J., Zeki, A. A., Peden, D. B., White, S. R., & Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network Research Group (2023). Treating asthma in the time of COVID. Journal of Allergy and Clinical Immunology, 151(4), 809-817. https://doi.org/10.1016/j.jaci.2022.12.800
Vancouver
Carr TF, Fajt ML, Kraft M, Phipatanakul W, Szefler SJ, Zeki AA, et al. Treating asthma in the time of COVID. Journal of Allergy and Clinical Immunology. 2023;151(4):809-817. doi:10.1016/j.jaci.2022.12.800
BibTeX
@article{Carr2023,
author = {Carr, Tara F and Fajt, Merritt L and Kraft, Monica and Phipatanakul, Wanda and Szefler, Stanley J and Zeki, Amir A and Peden, David B and White, Steven R and Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network Research Group, Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network Research Group},
title = {Treating asthma in the time of COVID},
journal = {Journal of Allergy and Clinical Immunology},
year = {2023},
volume = {151},
number = {4},
pages = {809--817},
doi = {10.1016/j.jaci.2022.12.800}
}
EUVIMED